B&L acquires Tubilux Pharma S.p.A

Article

Bausch & Lomb, has acquired the commercial assets of Italian ophthalmic pharmaceuticals business, Tubilux Pharma S.p.A, which markets proprietary, over-the-counter and branded generic products.

Bausch & Lomb, has acquired the commercial assets of Italian ophthalmic pharmaceuticals business, Tubilux Pharma S.p.A, which markets proprietary, over-the-counter and branded generic products. Its portfolio includes products for dry eye relief (Oxyal, Lipimix, and Vitadrop); for glaucoma (Cebrolux and Timolux); for anti-infective use (Oftaquix); and for anti-inflammatory use (Fluaton).

“This agreement more than doubles our presence in the Italian ophthalmic pharmaceuticals market,” said Charl van Zyl, head of Bausch & Lomb's Pharmaceuticals business for Europe, Middle East and Africa. “Bausch & Lomb is committed to expanding our portfolio offerings, and we believe that this investment will prove successful for the company, doctors and patients alike.”

Financial terms of the agreement were not disclosed.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.